Work

Dose-Escalation Trial of the ALK, MET & ROS1 Inhibitor, Crizotinib, in Patients with Advanced Cancer

Year: 2019

Type: article

Study design: Clinical Trial

Source: Future Oncology

DOI: 10.2217/fon-2019-0653

Authors: Jeffrey W Clark, D Ross Camidge, Eunice L Kwak, Robert G Maki, Geoffrey I Shapiro, Isan Chen, Weiwei Tan, Sophia Randolph, James G Christensen, Mark Ozeck, Yiyun Tang, Keith D Wilner, Ravi Salgia

Institutions: Massachusetts General Hospital, University of Colorado Cancer Center, Northwell Health, Cold Spring Harbor Laboratory, Harvard University, Dana-Farber Cancer Institute, Pfizer (United States), City Of Hope National Medical Center, City of Hope

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2991338674

FWCI: 1.47

Cites: 40

Cited by: 13

Related to: 10